You are here

Disease Prevention

Paxlovid Misses in Standard-Risk COVID-19

Updated findings from a nirmatrelvir/ritonavir (Paxlovid) trial in standard-risk COVID-19 suggest the antiviral's benefits are less clear for those not at high risk of severe outcomes.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Disease Prevention
howdy folks
Page loaded in 0.760 seconds.